| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
23,951,000 |
| Market
Cap: |
36.88(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.39 - $3.645 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile SCYNEXIS is a biotechnology company. Co. is developing its main product candidate, ibrexafungerp, as an intravenous/oral agent for multiple fungal indications in both the community and hospital settings. The U.S. Food and Drug Administration has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and Co. has commenced the commercialization of BREXAFEMME in the U.S. Co. also is continuing late-stage clinical development of ibrexafungerp for multiple indications, including the treatment of invasive fungal infections caused by Candida spp. (including C. auris) and Aspergillus spp. in hospitalized patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Taglietti Marco |
Chief Executive Officer |
• • – |
2019-04-17 |
4 |
B |
$1.63 |
$40,750 |
D/D |
25,000 |
506,000 |
2.81 |
- |
|
| Angulo Gonzalez David |
Chief Medical Officer |
• – – |
2019-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
271,790 |
|
- |
|
| Francois Eric |
Chief Financial Officer |
• – – |
2019-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
125,000 |
149,917 |
|
- |
|
| Sukenick Scott |
General Counsel |
• – – |
2019-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
102,959 |
|
- |
|
| Taglietti Marco |
Chief Executive Officer |
• • – |
2019-01-10 |
4 |
B |
$0.69 |
$17,250 |
D/D |
25,000 |
480,000 |
2.81 |
- |
|
| Angulo Gonzalez David |
Chief Medical Officer |
• – – |
2018-12-31 |
4 |
B |
$0.50 |
$5,951 |
D/D |
12,000 |
121,790 |
2.74 |
- |
|
| Taglietti Marco |
Chief Executive Officer |
• • – |
2018-12-31 |
4 |
B |
$0.46 |
$11,500 |
D/D |
25,000 |
455,000 |
2.81 |
- |
|
| Angulo Gonzalez David |
Chief Medical Officer |
• – – |
2018-09-06 |
4 |
B |
$1.27 |
$8,890 |
D/D |
7,000 |
108,790 |
2.74 |
- |
|
| Taglietti Marco |
Chief Executive Officer |
• • – |
2018-08-23 |
4 |
B |
$1.29 |
$32,250 |
D/D |
25,000 |
429,000 |
2.81 |
- |
|
| Angulo Gonzalez David |
Chief Medical Officer |
• – – |
2018-03-29 |
4 |
B |
$1.36 |
$8,160 |
D/D |
6,000 |
101,790 |
2.74 |
- |
|
| Angulo Gonzalez David |
Chief Medical Officer |
• – – |
2018-03-08 |
4 |
B |
$1.39 |
$9,730 |
D/D |
7,000 |
95,790 |
2.74 |
- |
|
| Hastings David C |
Director |
– • – |
2018-03-08 |
4 |
B |
$1.69 |
$19,999 |
D/D |
11,834 |
31,834 |
2.39 |
- |
|
| Sukenick Scott |
General Counsel |
• – – |
2018-03-08 |
4 |
B |
$1.69 |
$5,001 |
D/D |
2,959 |
2,959 |
2.74 |
- |
|
| Taglietti Marco |
Chief Executive Officer |
• • – |
2018-03-08 |
4 |
B |
$1.69 |
$169,000 |
D/D |
100,000 |
404,000 |
2.81 |
- |
|
| Francois Eric |
Chief Financial Officer |
• – – |
2018-03-08 |
4 |
B |
$1.69 |
$10,000 |
D/D |
5,917 |
24,917 |
2.74 |
- |
|
| Angulo Gonzalez David |
Chief Medical Officer |
• – – |
2018-03-08 |
4 |
B |
$1.69 |
$24,995 |
D/D |
14,790 |
88,790 |
2.74 |
- |
|
| Taglietti Marco |
Chief Executive Officer |
• • – |
2017-09-22 |
4 |
B |
$2.23 |
$22,300 |
D/D |
10,000 |
303,000 |
2.81 |
- |
|
| Taglietti Marco |
Chief Executive Officer |
• • – |
2017-08-23 |
4 |
B |
$1.85 |
$9,237 |
D/D |
4,993 |
292,000 |
2.81 |
- |
|
| Taglietti Marco |
Chief Executive Officer |
• • – |
2017-08-22 |
4 |
B |
$1.61 |
$11 |
D/D |
7 |
287,007 |
2.73 |
- |
|
| Taglietti Marco |
Chief Executive Officer |
• • – |
2017-08-15 |
4 |
B |
$1.61 |
$16,100 |
D/D |
10,000 |
287,000 |
2.81 |
- |
|
| Angulo Gonzalez David |
Chief Medical Officer |
• – – |
2017-08-11 |
4 |
B |
$1.55 |
$15,500 |
D/D |
10,000 |
72,000 |
2.74 |
- |
|
| Hastings David C |
Director |
– • – |
2017-06-21 |
4 |
B |
$1.75 |
$35,000 |
D/D |
20,000 |
20,000 |
2.39 |
- |
|
| Angulo Gonzalez David |
Chief Medical Officer |
• – – |
2017-05-12 |
4 |
B |
$1.70 |
$25,500 |
D/D |
15,000 |
62,000 |
2.74 |
- |
|
| Taglietti Marco |
Chief Executive Officer |
• • – |
2017-05-12 |
4 |
B |
$1.69 |
$42,250 |
D/D |
25,000 |
277,000 |
2.81 |
- |
|
| Taglietti Marco |
Chief Executive Officer |
• • – |
2016-12-21 |
4 |
B |
$3.30 |
$82,500 |
D/D |
25,000 |
251,000 |
2.81 |
- |
|
132 Records found
|
|
Page 3 of 6 |
|
|
0.07 (4.76%) 
